Health Yuan announced that recently, Sichuan Everbright, a subsidiary of its holding subsidiary Lizhu Group, received a “Drug Registration Certificate” issued by the State Drug Administration regarding the drug registration application for Banxia Baishu Tianma Soup granules. This drug is the company's first Class 3.1 new traditional Chinese medicine approved for marketing. As of the announcement and disclosure date, the total direct investment in research and development costs were about RMB 5.0102 million. Once the drug is marketed, it will not have a significant impact on the company's recent business performance, and drug production and sales are uncertain, reminding investors to be aware of the risks.

Health Yuan announced that recently, Sichuan Everbright, a subsidiary of its holding subsidiary Lizhu Group, received a “Drug Registration Certificate” issued by the State Drug Administration regarding the drug registration application for Banxia Baishu Tianma Soup granules. This drug is the company's first Class 3.1 new traditional Chinese medicine approved for marketing. As of the announcement and disclosure date, the total direct investment in research and development costs were about RMB 5.0102 million. Once the drug is marketed, it will not have a significant impact on the company's recent business performance, and drug production and sales are uncertain, reminding investors to be aware of the risks.